



Atty. Docket No.: 8654/2222 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wilson et al.  
Serial No.: 10/790,943  
Filed: March 2, 2004  
Entitled: Anti-Cancer Combinations

Examiner: DeLacroix, M.C.  
Group Art Unit: 1614  
Conf. No.: 2176

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katie Manzione

Name of Person Mailing Paper

*Katie Manzione*

Signature of Person Mailing Paper

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Pursuant to CFR § 1.97(c)(2), because this Statement is being submitted after the mailing of the first Office Action on the merits, the Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 8654/2222.

Respectfully submitted,

Date: January 25, 2006

Name: Matthew Beaudet  
Registration No.: 50,649  
Customer No.: 29933  
Edwards Angell Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

01/30/2006 RMEBRAHT 00000095 160085 10790943

01 FC:1806 180.00 DA

356144.1



USPTO Form 1449 U.S. Department of Commerce  
Patent and Trademark Office

### INFORMATION DISCLOSURE STATEMENT

Attorney Docket No.

8654/2222

Serial No.

10/790,943

Applicant(s): Wilson et al.

Filing Date: March 2, 2004

Group: 1614

### U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
.							
.							
.							
.							
.							
.							
.							

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
.								
.								
.								
.								
.								
.								
.								

### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

A.	Hill, et al., "Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid", International Journal of Cancer (1995), V. 63, No. 1, Pages 119-123.
B.	Wilson; "Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy"; 2000; International Journal of Radiation Oncology, Biology and Physics; 46(3): 706.
.	
.	
.	
.	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*\*Copies of references not provided at the time of this submission.